Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ondansetron in multiple sclerosis.

A D Macleod1

  • 1Psychiatric Consultation Services, Christchurch Hospital, Christchurch, New Zealand.

Journal of Pain and Symptom Management
|November 9, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early constipation predicts faster dementia onset in Parkinson's disease.

NPJ Parkinson's disease·2021
Same author

Untangling chronic pain and post-concussion symptoms: the significance of depression.

Brain injury·2018
Same author

Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls.

Parkinsonism & related disorders·2016
Same author

Motor complications in an incident Parkinson's disease cohort.

European journal of neurology·2015
Same author

Euthanasia and physician-assisted dying: editorial comment and reply to the Waikato GP survey findings by Dr Havill.

The New Zealand medical journal·2015
Same author

Impaired eye movements in post-concussion syndrome indicate suboptimal brain function beyond the influence of depression, malingering or intellectual ability.

Brain : a journal of neurology·2009
Same journal

Coping with Breathlessness in Individuals with Lung Diseases: A Systematic Review and Meta-Synthesis.

Journal of pain and symptom management·2026
Same journal

Growing the Next Generation of Hospice and Palliative Medicine Researchers.

Journal of pain and symptom management·2026
Same journal

Topical Amitriptyline, Ketamine, and Lidocaine Cream for Neuropathic Pain Control in Pediatric Oncology Patients.

Journal of pain and symptom management·2026
Same journal

Perceived Stigma, Psychological Distress, and Symptom Burden in Decompensated Cirrhosis.

Journal of pain and symptom management·2026
Same journal

Routine Urine Drug Screening in Palliative Care - A Call for Evidence Before Implementation.

Journal of pain and symptom management·2026
Same journal

Why We Should Rarely Override Surrogates.

Journal of pain and symptom management·2026
See all related articles

Ondansetron, a 5HT3 receptor antagonist, effectively managed chronic nausea and vertigo in two multiple sclerosis patients. This highlights palliative care

Area of Science:

  • Neuroscience
  • Pharmacology
  • Palliative Care

Background:

  • Multiple sclerosis (MS) is a chronic, degenerative neurological disease.
  • Patients with MS often experience debilitating symptoms like nausea and vertigo.
  • Palliative care for neurodegenerative diseases remains an under-addressed area.

Observation:

  • Two young women diagnosed with multiple sclerosis presented with persistent nausea and vertigo.
  • These symptoms significantly impacted their quality of life.
  • Standard treatments may not adequately address these specific neurological symptoms.

Findings:

  • The introduction and consistent use of ondansetron, a 5HT3 receptor antagonist, led to a significant improvement in symptoms.
  • Both patients experienced relief from chronic nausea and vertigo after ondansetron treatment.

Related Experiment Videos

  • The medication was well-tolerated, allowing for its maintenance.

    • Implications:

    • Ondansetron shows promise as an effective treatment for managing nausea and vertigo in multiple sclerosis patients.
    • This case study underscores the importance of targeted palliative care in neurodegenerative disease management.
    • Further research into ondansetron's efficacy and role in MS symptom management is warranted.